Clinical trials: Pioglitazone, completed
Type 2 Diabetes
Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19
The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.
- Trial name
- NCT04535700
- Testing
- Pioglitazone 30 mg, standard of care
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Type 2 Diabetes
Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
- Trial name
- NCT01882907
- Testing
- vildagliptin, Pioglitazone
- Where
- 15 sites in South Korea
- Volunteers
- 287 people
- Sponsor
- Pusan National University Hospital
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions
Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride)…
- Trial name
- NCT01800240
- Testing
- Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Diabetes Mellitus
A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS
We hypothesized that a portion controlled diet would prevent the weight gain associated with the use of a peroxisome profliferator-activated receptor-gamma (PPAR-g).
- Trial name
- TAKE II (NCT00219440)
- Testing
- Actos plus standard diet, Actos plus structured diet, Metformin plus standard diet
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Pennington Biomedical Research Center
Type 2 Diabetes Mellitus
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
- Trial name
- NCT00106808
- Testing
- Muraglitazar, Pioglitazone
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 1,440 people
- Sponsor
- Bristol-Myers Squibb
Cystic Fibrosis
Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease. Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens…
- Trial name
- NCT00322868
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University Hospitals Cleveland Medical Center
Type 2 Diabetes Mellitus
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in…
- Trial name
- NCT00789750
- Testing
- Colesevelam, Pioglitazone
- Where
- 141 sites in United States
- Volunteers
- 562 people
- Sponsor
- Daiichi Sankyo
Polycystic Kidney Diseases
Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
Chronic Kidney Disease (CKD) is associated with bone changes and very high fracture rates. A component of bone is marrow. Bone marrow fat is increased in patients with CKD compared to those in the normal population of the same…
- Trial name
- NCT02739750
- Testing
- No intervention
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Diabetes
Role of Pioglitazone in Preventing Diabetes
A three year prospective, double blinded, placebo controlled, randomized clinical trial in impaired glucose tolerance (IGT) subjects to study the effect of pioglitazone in preventing the conversion to Diabetes.
- Trial name
- NCT00276497
- Testing
- Pioglitazone
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.V. Hospital for Diabetes
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)
This study will examine the safety and efficacy of the addition of omarigliptin in Japanese participants with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy and oral antihyperglycemic agent…
- Trial name
- NCT01697592
- Testing
- Omarigliptin
- Volunteers
- 585 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
- Trial name
- NCT01686711
- Testing
- AD-4833 15 mg, AD-4833 30 mg
- Where
- 25 sites in Japan
- Volunteers
- 207 people
- Sponsor
- Takeda
Head and Neck Cancer, Oral Leukoplakia
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
This phase II trial studies how well pioglitazone hydrochloride works in preventing head and neck cancer in patients who have oral leukoplakia.
- Trial name
- NCT00099021
- Testing
- pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes Mellitus
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period…
- Trial name
- GetGoal-Duo1 (NCT00975286)
- Testing
- Lixisenatide (AVE0010), Insulin glargine, Pen auto-injector
- Where
- 140 sites in United States, Argentina and 24 more
- Volunteers
- 446 people
- Sponsor
- Sanofi
Diabetes Mellitus
Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease
The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.
- Trial name
- NCT00521742
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 300 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086502
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone, Metformin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Lipodystrophy, HIV Infection
Metabolic Abnormalities in HIV-infected Persons
The purpose of this study is to examine the relationship between insulin resistance and changes in body fat distribution in HIV-infected persons.
- Trial name
- NCT01612858
- Testing
- Metformin, Pioglitazone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tufts Medical Center
Coronary Artery Disease, Angina Pectoris
Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients
Patients with diabetes have worse outcomes after percutaneous coronary intervention (PCI) procedures, compared to those patients without diabetes.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Type 2 Diabetes Mellitus, Percutaneous Coronary Intervention
- Trial name
- PPAR-G (NCT00819325)
- Testing
- pioglitazone, oral hypoglycemic agents
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Queen Elizabeth II Health Sciences Centre
Diabetes Mellitus Type 2
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes.
- Trial name
- EPHIC-DIA2 (NCT06851962)
- Testing
- Metformin, Dulaglutide, Semaglutide 1.0 mg
- Where
- 3 sites in Spain
- Volunteers
- 92 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Diabetes Mellitus, Type 2
Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
This trial will explore the various advantages and possible disadvantages of pioglitazone and insulin glargine when added to monotherapy.
- Trial name
- NCT00384215
- Testing
- insulin glargine [rDNA origin] injection
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- Sanofi
Type 2 Diabetes
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and…
- Trial name
- NCT00806520
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- HealthPartners Institute